Centene Corporation CNC (NYSE:CNC) continues to reposition and diversify its service offerings, with moves such as expanding the CHS network, shifting the AcariaHealth facility, and divesting Apixio. This has been met with varied analyst ratings, from 'Hold' at Baird to an 'Equal Weight' ranking at Stephens. Despite periodic underperformance compared to competitors, Centene is demonstrating confidence, even amidst Medicaid challenges, and retains robust financials despite current stock weaknesses. Interest in Centene has risen sharply, while stakeholders like TD Asset Management lower their stakes. Recent partnerships with Cityblock and McCormack Baron Salazar aim to enhance value-based care, and state contracts augment Centene's significant market position. Recognitions include being named one of the top 50 companies for diversity by FAIR360 and maintaining an A-Grade valuation. Profitability has been robust, with 47% earnings growth recorded, beating the long-term trend, and positive guidance issued for FY24. However, there are concerns on the horizon with potential headwinds impacting the stock.
Centene Corporation CNC News Analytics from Thu, 13 Jul 2023 07:00:00 GMT to Sun, 02 Jun 2024 05:37:26 GMT -
Rating -3
- Innovation 4
- Information 5
- Rumor -3
